Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

Clinical trial NCT02977052 · UNKNOWN

Trial details

NCT number: NCT02977052
Sponsor: The Netherlands Cancer Institute
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma Stage III

Start date: 2016-11-24
Primary completion: 2020-01-03
Enrollment: 186

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.